Advertisement

Receptor Mediation of the Discriminative Stimulus Properties of Phencyclidine and Sigma-Opioid Agonists

  • R. L. Balster
  • J. Willetts
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 4)

Abstract

Evidence has accumulated that the discriminative stimulus effects of phencyclidine (PCP) may be transduced by a specific receptor in mammalian brain. Two major lines of evidence support this hypothesis. One is the structure-activity correlation that arylcyclohexylamine analogs of PCP have for PCP-like discriminative effects and displacement of [3H]PCP binding. The other, even stronger, evidence is that representatives of some nonarylcyclohexylamine classes of drugs are both generalized from PCP and have activity at PCP-binding sites. These include the psychotomimetic sigma-agonist opioids such as (+)-N-allylnormetazocine (NANM), the 1,3-substituted dioxolanes dexoxadrol and etoxadrol and some benz(f)isoquinolines. Early evidence suggested that there may be a complete overlap in the discriminative effects and receptor systems for PCP and sigma-agonists, and there continues to be evidence to support the commonality of these drug groups. On the other hand, binding studies with radiolabeled sigma agonists have revealed a non-PCP site. The role of this site in the behavioral actions of sigma-agonists is at present unknown. PCP analogs and other PCP-like drugs also can function as reinforcers for self-administration behavior, suggesting that the same cellular mechanisms may be responsible for both discriminative and reinforcing stimulus effects of these drugs. PCP has been shown to block many of the in vitro and in vivo effects of N-methyl-D-aspartate (NMDA), a putative specific agonist for a subtype of excitatory amino acid receptor. Recent evidence that NMDA antagonists are generalized from PCP in rats and pigeons provides evidence that modification of excitatory amino neurotransmission may be a physiological function of the PCP receptor and that this receptor complex may be involved in PCP’s discriminative stimulus effects.

Keywords

Discriminative Stimulus Discriminative Stimulus Effect Sigma Receptor Discriminative Stimulus Property Receptor Mediation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by iV-methyl-as-partate. Br J Pharmacol 79:565–575PubMedGoogle Scholar
  2. Balster RL (1986a) Clinical implications of behavioral pharmacology research on phencyclidine. In: Clouet DH (ed) Phencyclidine: an update. Natl Inst Drug Abuse Res Monogr 64:148–162 [DHHS publication (ADM) 86–1443]Google Scholar
  3. Balster RL (1986b) (+)-3-PPP antagonizes the discriminative stimulus effects of (+)-Ar-allyl-normetazocine. Eur J Pharmacol 127:283–286PubMedCrossRefGoogle Scholar
  4. Balster RL (1987) Drugs with a high affinity for 3H-(+)-JV-allylnormetazocine (NANM) binding do not have activity in (+)-NANM discrimination in rats. Fed Proc 46:(to be published)Google Scholar
  5. Balster RL, Brady KT (1982) Similarities in the discriminative stimulus properties of (+)-N-allylnormetazocine and phencyclidine in rats. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical, Amsterdam, pp 99–108Google Scholar
  6. Balster RL, Johanson CE, Harris RT, Schuster CR (1973) Phencyclidine self administration in the rhesus monkey. Pharmacol Biochem Behav 1:167–172CrossRefGoogle Scholar
  7. Brady KT, Balster RL (1981) Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey. Pharmacol Biochem Behav 14:213–218PubMedCrossRefGoogle Scholar
  8. Brady KT, Balster RL (1982a) Discriminative stimulus properties of ketamine stereoisomers in pheneyclidine-trained rats. Pharmacol Biochem Behav 17:291–295PubMedCrossRefGoogle Scholar
  9. Brady KT, Balster RL (1982b) Discriminative stimulus properties of stereoisomers of cyclazocine in phencyclidine-trained squirrel monkeys. Life Sci 31:541–549PubMedCrossRefGoogle Scholar
  10. Brady KT, Balster RL, May EL (1982) Stereoisomers of TV-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 215:178–180PubMedCrossRefGoogle Scholar
  11. Browne RG (1986) Discriminative stimulus properties of PCP mimetics. In: Clouet DH (ed) Phencyclidine: an update. Natl Inst Drug Abuse Res Monogr 64:134–147 [DHHS publication (ADM) 86–1443]Google Scholar
  12. Browne RG, Welch WM (1982) Stereoselective antagonism of phencyclidine’s discriminative properties by adenosine receptor agonists. Science 217:1157–1159PubMedCrossRefGoogle Scholar
  13. Browne RG, Welch WM, Kozlowski MR, Duthu G (1983) Antagonism of PCP discrimination by adenosine analogs. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 639–666Google Scholar
  14. Contreras PC, Rice KC, Jacobson AE, O’Donohue TL (1986) Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur J Pharmacol 121:9–18PubMedCrossRefGoogle Scholar
  15. Domino EF (1964) Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol 6:303–347PubMedCrossRefGoogle Scholar
  16. Gundlach AL, Largent BL, Snyder SH (1986) Characterization of phencyclidine and sigma receptor-binding sites in brain. In: Clouet DH (ed) Phencyclidine: an update. Natl Inst Drug Abuse Res Monogr 64:1–13 [DHHS publication (ADM) 86–1443]Google Scholar
  17. Hayes BA, Balster RL (1985) Anticonvulsant properties of phencyclidine-like drugs in mice. Eur J Pharmacol 117:121–125PubMedCrossRefGoogle Scholar
  18. Holtzman SG (1982) Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology 77:295–300PubMedCrossRefGoogle Scholar
  19. Itzhak Y, Hiller JM, Simon EJ (1985) Characterization of specific binding sites for [3H](c/)-jV-allylnormetazocine in rat brain membranes. Mol Pharmacol 27:46–52PubMedGoogle Scholar
  20. Johnson KM (1983) Partial characterization of the specific binding of 3H-iV-allylnormetazocine (SKF 10047) to rat brain membranes. Res Commun Subst Abuse 4:33–47Google Scholar
  21. Johnson KM, Snell LD (1986) Involvement of dopaminergic, cholinergic, and glutaminergic mechanisms in the actions of phencyclidine-like drugs. In: Clouet DH (ed) Phencyclidine: an update. Natl Inst Drug Abuse Res Monogr 64:52–66 [DHHS publication (ADM) 86–1443]Google Scholar
  22. Koek W, Woods JH, Ornstein P (1986) Phencyclidine like behavioral effects induced by systemic administration of the excitatory amino acid antagonist, 2-amino-5-phosphonovalerate. Life Sei 39:973–978CrossRefGoogle Scholar
  23. Largent BL, Gundlach AL, Snyder SH (1984) Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-iV-(l-propyl)piperidine. Proc Natl Acad Sei USA 81:4983–4987CrossRefGoogle Scholar
  24. Lazdunski M, Bidard JN, Romey G, Tourneur Y, Vignon J, Vincent JP (1983) The different sites of action of phencyclidine and its analogues in nervous tissue. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 83–106Google Scholar
  25. Leander JD, Zimmerman DM, Ornstein PL (1986) Antagonism of the behavioral effects of N-methyW-aspartic acid by phencyclidine-like drugs. Fed Proc 45:430 (abstract)Google Scholar
  26. Lukas SE, Griffiths RR, Brady JY, Wurster RM (1984) Phencyclidine-analogue self-injection by the baboon. Psychopharmacology 83:316–320PubMedCrossRefGoogle Scholar
  27. Maragos WF, Chu DCM, Greenamyre JT, Penny JB, Young AB (1986) High correlation between the localization of [3H]TCP binding and NMDA receptors. Eur J Pharmacol 123:173–174PubMedCrossRefGoogle Scholar
  28. Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL (1984) Stereoisomers of [3H]-iV-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther 231:539–544PubMedGoogle Scholar
  29. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine-and nalorphine-like drugs on the nondependent and morphine dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–531PubMedGoogle Scholar
  30. Mendelsohn LG, Kerchner GA, Kalra V, Zimmerman DM, Leander JD (1984) Phencyclidine receptors in rat brain cortex. Biochem Pharmacol 33:3529–3535PubMedCrossRefGoogle Scholar
  31. Mendelsohn LG, Kalra V, Johnson BG, Kerchner GA (1985) Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor. J Pharmacol Exp Ther 233:597–602PubMedGoogle Scholar
  32. Murray TF, Leid ME (1984) Interaction of dextrorotatory opioids with phencyclidine recognition sites in rat brain membranes. Life Sci 34:1899–1911PubMedCrossRefGoogle Scholar
  33. Pasternak GW, Carroll-Buatti M, Spiegel K (1981) The binding and analgesic properties of a sigma opiate, SKF 10,047. J Pharmacol Exp Ther 219:192–198PubMedGoogle Scholar
  34. Poling AD, White FJ, Appel JB (1979) Discriminative stimulus properties of phencyclidine. Neuropharmacology 18:459–463PubMedCrossRefGoogle Scholar
  35. Quirion R, Hammer RP, Herkenham M, Pert CB (1981) Phencyclidine (angel dust)/σ “opiate” receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci USA 78:5881–5885PubMedCrossRefGoogle Scholar
  36. Quirion R, O’Donohue TL, Everist H, Pert A, Pert CB (1983) Phencyclidine receptors and possible existence of an endogenous ligand. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 667–684Google Scholar
  37. Risner ME (1982) Intravenous self administration of phencyclidine and related compounds in the dog. J Pharmacol Exp Ther 221:637–644PubMedGoogle Scholar
  38. Shannon HE (1981a) Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J Pharmacol Exp Ther 216:543–551PubMedGoogle Scholar
  39. Shannon HE (1981b) Pharmacological evaluation of jV-allylnormetazoeine (SKF 10,047) on the basis of its discriminative stimulus properties in the rat. J Pharmacol Exp Ther 225:144–152Google Scholar
  40. Shannon HE (1983) Discriminative stimulus effects of phencyclidine: structure-activity relationships. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 311–336Google Scholar
  41. Sircar R, Nichtenhauser R, Ieni JR, Zukin SR (1986) Characterization and autoradiographic visualization of (+)-[3H]SKF10,047 binding in rat and mouse brain: further evidence for phencyclidine/“sigma opiate” receptor commonality. J Pharmacol Exp Ther 237:681–688PubMedGoogle Scholar
  42. Slifer BL, Balster RL (1983) Reinforcing properties of stereoisomers of the putative sigma agonists iV-allylnormetazocine and cyclazocine in rhesus monkeys. J Pharmacol Exp Ther 225:522–528PubMedGoogle Scholar
  43. Slifer BL, Balster RL (1985a) Phencyclidine-like discriminative stimulus properties of the stereoisomers of dioxadrol. Subst Alcohol Actions Misuse 5:273–280Google Scholar
  44. Slifer BL, Balster RL (1985b) Phencyclidine-like behavioral effects of stereoisomers of beta-cyclazocine. Paper presented at the American College of Neuropsychopharmacology, MauiGoogle Scholar
  45. Snell LD, Johnson KM (1985) Antagonism of iV-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyelidine-like drugs and its relationship to turning behavior. J Pharmacol Exp Ther 235:50–57PubMedGoogle Scholar
  46. Stringer JL, Greenfield LJ, Hackett JT, Guyenet PG (1983) Blockade of long-term potentiation by phencyclidine and opiates in the hippocampus in vivo and in vitro. Brain Res 280:127–138PubMedCrossRefGoogle Scholar
  47. Su TP (1982) Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inac-cessible sites in guinea-pig brain. J Pharmacol Exp Ther 223:284–290PubMedGoogle Scholar
  48. Su TP, Cone EJ, Shannon H, Vaupel DB (1980) Relative potencies of phencyclidine and analogs in the opiate receptor binding assay: correlation with relative potencies determined in vivo in mouse and rat. Res Commun Subst Abuse 1:85–87Google Scholar
  49. Tam SW (1983) Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Natl Acad Sci USA 80:6703–6707PubMedCrossRefGoogle Scholar
  50. Tam SW (1985) (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, µ, κ, σ and phencyclidine binding sites in guinea pig brain membranes. Eur J Pharmacol 109:33–41.PubMedCrossRefGoogle Scholar
  51. Tam SW, Cook L (1984) Sigma opiates and certain antipsychotic drugs mutually inhibit (+)[3H]SKF-10,047 and [3H]-haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA 81:5618–5621PubMedCrossRefGoogle Scholar
  52. Tang AH, Cangelosi AA, Code RA, Franklin SR (1984) Phencyclidine-like behavioral effects of 2-methyl-3,3-diphenyl-3-propanolamine (2-MDP). Pharmacol Biochem Behav 20:209–213PubMedCrossRefGoogle Scholar
  53. Vaupel DB (1983) Phencyclidine studies in the dog: pharmacology of PCP, profiles of eight analogues abused by man and the similarity of PCP to the opioid NANM (iV-allylnormetazocine or SKF 10,047). In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 347–368Google Scholar
  54. Vaupel DB, Jasinski DR (1979) Acute single dose effects of phencyclidine (PCP) in the dog. Fed Proc 38:435Google Scholar
  55. Vincent JP, Cavey D, Kamenka JM, Geneste P, Lazdunski M (1978) Interaction of phencyclidine with the muscarinic and opiate receptors in the central nervous system. Brain Res 152:176–182PubMedCrossRefGoogle Scholar
  56. Vincent JP, Kartalovski B, Geneste P, Kamenka JM, Lazdunski M (1979) Interaction of phencyclidine (“angel dust”) with a specific receptor in rat brain membranes. Proc Natl Acad Sci USA 76:4678–4682PubMedCrossRefGoogle Scholar
  57. Vincent JP, Vignon J, Kartalovski B, Lazdunski M (1981) Receptor sites for phencyclidine in mammalian brain and peripheral organs. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP, Ann Arbor, pp 83–103Google Scholar
  58. Willetts J, Balster RL (1987) MK-801 has potent phencyclidine-like discriminative stimulus effects in rats. Fed Proc 46:(to be published)Google Scholar
  59. Willetts J, Chapman MY, Balster RL (1986) Discriminative stimulus effects of 2-amino-7-phosphonoheptanoic acid (APH) in phencyclidine-trained rats. Soc Neurosci Abs 12:909Google Scholar
  60. Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iverson LL (1986) The anticon: vulsant MK-801 is a potent JV-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104–7108PubMedCrossRefGoogle Scholar
  61. Young AM, Woods JH (1981) Maintenance of behavior by ketamine and related compounds in rhesus monkeys with different self administration histories. J Pharmacol Exp Ther 218:720–727PubMedGoogle Scholar
  62. Zenk P, May EL, Balster RL (1986) Synthesis of the diastereoisomers of 2-ethyl-2-phenyl-4-(2-piperidyl)-l,3-dioxolane (etoxadrol) as probes of the phencyclidine receptor. Paper presented at the annual meeting of the Virginia Academy of Sciences, HarrisonburgGoogle Scholar
  63. Zimmerman DM, Woods JH, Hynes MD, Cantrell BE, Reamer M, Leander JD (1983) Discovery and characterization of the phencyclidine-like actions of a new series of benz(f)isoquino-line derivatives. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines. NPP, Ann Arbor, pp 59–70Google Scholar
  64. Zukin RS, Zukin SR (1981) Demonstration of [3H]cyclazocine binding to multiple opiate receptor types. Mol Pharmacol 20:246–254PubMedGoogle Scholar
  65. Zukin RS, Zukin SR (1983) A common receptor for phencyclidine and the sigma opiates. In: Kamenka JM, Domino EF, Geneste P (eds) Phencyclidine and related arylcyclohexylamines: present and future applications. NPP, Ann Arbor, pp 107–124Google Scholar
  66. Zukin SR, Zukin RS (1979) Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 76:5372–5376PubMedCrossRefGoogle Scholar
  67. Zukin SR, Zukin RS (1981) Identification and characterization of [3H]phencyclidine binding to specific brain receptor sites. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP, Ann Arbor, pp 105–130Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. L. Balster
    • 1
  • J. Willetts
    • 1
  1. 1.Department of Pharmacology and ToxicologyMedical College of Virginia, Virginia Commonwealth UniversityRichmondUSA

Personalised recommendations